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BACKGROUND: Data on predictors of long-term clinical outcomes after 
catheter ablation of atrial fibrillation (AF) are limited. We sought to assess 
the association of baseline covariates with clinical outcomes in the 750 
patients with drug-refractory paroxysmal AF enrolled in FIRE AND ICE.
METHODS: In a 2-part analysis, univariate and multivariable Cox 
regression models were first used to identify baseline patient 
characteristics predictive of catheter ablation efficacy determined by the 
clinical end points of (1) atrial arrhythmia recurrence (primary efficacy 
failure), (2) cardiovascular rehospitalization, and (3) repeat ablation. 
Propensity score stratification methods were then used to account for 
differences in baseline characteristics between sexes.
RESULTS: Female sex (hazard ratio [HR], 1.37; 95% confidence interval 
[CI], 1.08–1.73; P=0.010) and prior direct current cardioversion (HR, 
1.40; 95% CI, 1.07–1.82; P=0.013) were independently associated with 
atrial arrhythmia recurrence. Female sex (HR, 1.36; 95% CI, 1.02–1.80; 
P=0.035) and hypertension (HR, 1.48; 95% CI, 1.09–2.00; P=0.013) 
independently predicted cardiovascular rehospitalization. A longer 
history of AF (HR, 1.03; 95% CI, 1.00–1.06; P=0.039) increased the rate 
of repeat ablation. Women continued to have higher rates of primary 
efficacy failure and cardiovascular rehospitalization after propensity score 
adjustment, with adjusted HRs of 1.51 (95% CI, 1.16–2.18; P<0.05) and 
1.40 (95% CI, 1.15–2.17; P<0.05), respectively.
CONCLUSIONS: After catheter ablation of paroxysmal AF, female sex was 
associated with an almost 40% increase in the risks of primary efficacy 
failure and cardiovascular rehospitalization. Primary efficacy failure was 
also adversely impacted by a history of direct current cardioversion, 
whereas hypertension had a negative impact on cardiovascular 
rehospitalization. History of AF was the only predictor of repeat ablation.
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Pulmonary vein isolation via catheter ablation is ac-cepted as a safe and effective treatment for atrial fibrillation (AF), but a better understanding of pa-
tients who are/are not likely to benefit from catheter 
ablation may further advance treatment strategies. Sev-
eral database reviews have identified sex, age, socio-
economic, and racial/ethnic dependent differences in 
long-term outcomes of catheter ablation for AF.1–4 Al-
though the number of subjects examined in these stud-
ies have been robust, the analyses have been limited to 
the few patient baseline characteristics previously re-
corded in these medical database reviews.1–4 There is a 
lack of large cohort analyses that evaluate an extensive 
set of baseline data to identify preprocedural patient 
characteristics predictive of long-term outcomes after 
catheter ablation for AF.
The present study evaluates the 750 subjects treat-
ed in the FIRE AND ICE trial (without differentiating by 
catheter ablation modality)5–8 across 22 distinct baseline 
patient characteristics. All 22 characteristics were asso-
ciated with 3 separate, predefined, long-term measures 
of clinical outcome: atrial arrhythmia recurrence (prima-
ry efficacy failure), cardiovascular rehospitalization, and 
repeat catheter ablation. Secondary analyses were uti-
lized to test differences in male and female outcomes 
for a more comprehensive understanding of the impact 
sex has on clinical success after catheter ablation of AF.
METHODS
As additional publications of FIRE AND ICE data are in prep-
aration, the current data, analytical methods, and study 
materials will not be made available to other researchers 
for purposes of reproducing the results or replicating the 
procedure.
WHAT IS KNOWN?
• Pulmonary vein isolation is the cornerstone of cath-
eter ablation for the treatment of patients with 
paroxysmal atrial fibrillation; yet, some patients 
still experience arrhythmia recurrence and undergo 
repeat ablation and cardiovascular rehospitaliza-
tion after pulmonary vein isolation.
• Previous database reviews have shown that long-
term clinical outcome failures of catheter abla-
tion are associated with select baseline patient 
characteristics.
WHAT THE STUDY ADDS?
• Female sex is associated with a ≈40% higher risk 
than male sex of primary efficacy failure and car-
diovascular rehospitalization after catheter abla-
tion of atrial fibrillation, indicating a need for 
increased efforts in monitoring and earlier treat-
ment of women to reduce the risk of arrhythmia 
recurrence.
• A history of direct current cardioversion, hyperten-
sion, and a longer history of atrial fibrillation inde-
pendently predicted poorer clinical outcomes after 
catheter ablation of atrial fibrillation.
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Study Design and Data Source
FIRE AND ICE was a multicenter (16 centers in 8 European 
countries) randomized (1:1) comparison of 2 catheter abla-
tion modalities (cryoballoon versus radiofrequency current 
ablation) used to treat patients with drug-refractory symp-
tomatic paroxysmal AF.5–8 The study design, procedural 
methods, and predefined primary and secondary study end 
points have been published previously.5–8 Approval for this 
study was granted by each local institution’s review board, 
and informed consent was obtained from each subject. In 
brief, 762 subjects were enrolled and randomized, 750 of 
whom were treated with catheter ablation and comprised 
the modified intention-to-treat cohort.5 The ablation strat-
egy used in both treatment groups was pulmonary vein 
isolation without any further ablation in the left atrium.5 
Subjects were enrolled from January 2012 to January 2015 
and were followed for a maximum of 33 months, with an 
average follow-up of 1.5 years.5
In the trial, the primary efficacy end point was the time to 
first documented occurrence, outside the landmark 90-day 
blanking period, of (1) recurrence of atrial arrhythmia (AF >30 
seconds, atrial flutter, or atrial tachycardia), (2) prescription of an 
antiarrhythmic drug, or (3) repeat catheter ablation.5 Predefined 
secondary end points included cardiovascular rehospitalization 
and repeat catheter ablation for atrial arrhythmias that occurred 
throughout the entire study follow-up (including the blanking 
period; these measurements were total observed events rather 
than time to first recordings).5–7 The primary objectives of the 
current data analyses were to identify the baseline patient 
demographic characteristics predictive of clinical patient out-
comes, specifically primary efficacy, cardiovascular rehospitaliza-
tion, and repeat catheter ablation. The current analyses utilized 
the same definition of outcomes as those previously published 
for the primary and secondary end points.5–8
Statistics
Previous publications reporting subgroup interaction tests 
concluded that the treatment effect (difference between 
cryoballoon and radiofrequency current efficacy) was con-
sistent across predefined subgroups;5,6 therefore, the ran-
domization arms from the FIRE AND ICE trial (cryoballoon 
and radiofrequency current) were pooled into a single, 
large cohort of patients for statistical examination in this 
study. All patients who were enrolled, randomized, and 
treated with catheter ablation (modified intention-to-treat 
cohort) were included, which is consistent with previous 
publications of this data set.5–8 Continuous data are pre-
sented as means and SDs, and discrete data are presented 
as counts and percentages. Demographic and procedural 
differences between sexes were assessed with a t test for 
continuous variables and Fisher exact test for categorical 
variables.
Two types of analysis were completed in this study. The first 
analysis identified baseline patient characteristics predictive of 
efficacy after catheter ablation. The second analysis further 
investigated differences in outcomes by sex. The distribution 
of patients included in these analyses is given in Figure 1.
Univariate and multivariable Cox regression models were 
used to assess the association between baseline patient 
characteristics and the risk of a study end point occurring 
in a subject. Each patient baseline characteristic was exam-
ined by univariate analysis with the study outcome denoted 
as the dependent variable and baseline patient characteris-
tic as the covariate. Significant covariates (P<0.05) identi-
fied from the univariate analyses were then included in a 
multivariable Cox regression model. Covariates that were 
significant in the multivariable model (P<0.05) were con-
sidered independently associated with the study outcome. 
Separate univariate and multivariable models were utilized 
for each of the 3 clinical outcomes, and hazard ratios (HRs) 
were estimated with Cox regression from both the univari-
ate models (HR) and multivariable models (HRMV adj). Kaplan–
Meier plots were used to illustrate the significant patient 
characteristics.
To account for differences in baseline characteristics 
between men and women, propensity score (PS) stratifica-
tion methods were utilized to estimate an adjusted HR for 
efficacy between men and women.9 Seventeen baseline 
covariates were included in the PS analysis (Table I in the Data 
Supplement). Patients were divided equally into 5 strata using 
PS quintiles, HRs were calculated by Cox proportional haz-
ards regression for each strata, and the overall adjusted HR 
was obtained using inverse-variance weighting. Interaction 
tests (with sex by PS quintile as an interaction term) were 
conducted with Cox regression models to check the balance 
of demographics within each quintile and the consistency of 
outcomes across quintiles. Bootstrap methods were used to 
calculate a 95% confidence interval (CI).
All analyses were conducted using SAS/STAT software 
(version 13.1; 2012 SAS Institute) and R statistical package, 
version 3.2.2 (https://www.r-project.org).
RESULTS
Baseline Characteristics
A total of 750 subjects with symptomatic paroxysmal 
AF refractory to class I or III antiarrhythmic drugs or 
Figure 1. Flowchart of patients enrolled and included in analyses.  
The total cohort of 750 patients was entered into univariate and multivariable 
Cox regression analyses. Propensity score-matched patients were subsequently 
analyzed to assess the impact of sex on outcomes.
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β-blockers were enrolled, randomized, and treated 
in the study. The mean patient age was 60.0±9.5 
years, and 457 patients (61%) were men. Patients 
were diagnosed with AF for a mean of 4.6±5.2 years 
before the index ablation, and 174 patients (23%) 
had a history of direct current cardioversion (DCCV; 
Table 1).
Predictors of Efficacy: Relationship 
Between Baseline Characteristics and the 
Primary Outcome
The impact of the 22 baseline demographic characteris-
tics on recurrence of AF assessed by univariate statistical 
testing (Table 2) revealed that both sex (P=0.015) and 
prior DCCV (P=0.021) were significant predictors of AF 
recurrence. Subsequent multivariable modeling con-
firmed that both sex and prior DCCV were independent 
predictors of AF recurrence (Table 3; Figure 2). Specifi-
cally, female sex was associated with a 37% increase in 
the risk of primary efficacy end point failure (HRMV adj, 
1.37; 95% CI, 1.08–1.73; P=0.010), and DCCV before 
enrollment was associated with a 40% increase in the 
risk of primary efficacy failure (HRMV adj, 1.40; 95% CI, 
1.07–1.82; P=0.013).
Predictors of Efficacy: Relationship 
Between Baseline Characteristics and 
Secondary Outcomes
Univariate statistical testing determined that age 
(P=0.012), body mass index (P=0.035), sex (P=0.008), 
hypertension (P=0.001), and systolic blood pressure 
(P=0.034) were all significantly associated with cardio-
vascular rehospitalization; the only predictor of repeat 
ablation was history of AF (P=0.039; Table 2).
Table 1. Baseline Patient Characteristics
 Total (N=750) Women (n=293) Men (n=457) P Value*
Age, y 60±10 64±8 57±10 <0.001
Body mass index, kg/m2 28±5 28±5 28±4 0.157
Systolic BP, mm Hg 134±18 135±19 133±18 0.142
Diastolic BP, mm Hg 79±11 77±11 80±11 <0.001
Diabetes mellitus, type I or II 60 (8) 21 (7) 39 (9) 0.582
GFR, mL/min per 1.73 m2 79±19 74±18 82±19 <0.001
History of AF, y 4.6±5.2 4.6±5.2 4.6±5.2 0.987
History of atrial flutter 128 (17) 32 (11) 96 (21) <0.001
History of CAD 63 (8) 16 (5) 47 (10) 0.022
Hyperlipidemia 221 (29) 90 (31) 131 (29) 0.566
Hypertension 436 (58) 183 (62) 253 (55) 0.058
Left atrial volume, mL† 59±30 59±31 58±30 0.923
LVEDD, mm† 50±7 48±5 51±7 <0.001
LVEF, %† 63±7 64±6 62±7 0.004
Left atrial diameter, mm† 40.7±6.1 39.9±6.5 41.2±5.8 0.012
NYHA functional class    0.002
  No heart failure 540 (72) 194 (66) 346 (76)  
  NYHA class I 87 (12) 34 (12) 53 (12)  
  NYHA class II 122 (16) 65 (22) 57 (12)  
  No NYHA class available 1 (0.1) 0 (0) 1 (0.2)  
PCI 40 (5) 12 (4) 28 (6) 0.248
Peripheral artery disease 4 (0.5) 2 (0.7) 2 (0.4) 0.646
Prior DCCV 174 (23) 63 (22) 111 (24) 0.425
Prior myocardial infarction 18 (2) 4 (1) 14 (3) 0.220
Prior stroke or TIA 28 (4) 12 (4) 16 (4) 0.696
Values are mean±SD or n (%). AF indicates atrial fibrillation; BP, blood pressure; CAD, coronary artery disease; DCCV, direct 
current cardioversion; GFR, glomerular filtration rate; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection 
fraction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; and TIA, transient ischemic attack.
*2-sample t test for continuous variables and Fisher exact test for categorical variables.
†Left atrial diameter data reported for 584 subjects, left ventricular ejection fraction data reported for 510 subjects, left 
ventricular end-diastolic diameter data reported for 411 subjects, and left atrial volume data reported for 87 subjects.
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Sex and hypertension remained statistically significant 
in multivariable modeling, indicating that they were inde-
pendent predictors of cardiovascular rehospitalization. 
Female sex was associated with a 36% increase (HRMV adj, 
1.36; 95% CI, 1.02–1.80; P=0.035), and a baseline his-
tory of hypertension was associated with a 48% increase 
(HRMV adj, 1.48; 95% CI, 1.09–2.00; P=0.013) in the risk 
of cardiovascular rehospitalization. History of AF (in 
years) was the only statistically significant covariate pre-
dicting repeat ablation, and thus, no multivariable model 
was estimated. The HR for years with AF was 1.03 (95% 
CI, 1.00–1.06; P=0.039), indicating that each additional 
year of diagnosed AF history was associated with a 3% 
increased risk of repeat ablation.
Outcomes According to Sex: Baseline 
Patient Characteristics
In the FIRE AND ICE data set, female and male patients 
presented with similar histories of AF (4.6±5.2 versus 
4.6±5.2 years; P=0.987), body mass index (28±5 ver-
sus 28±4 kg/m2; P=0.157), and baseline systolic blood 
pressure (135±19 versus 133±18 mm Hg; P=0.142), 
respectively (Table 1). However, women exhibited base-
line clinical characteristics predisposing them to an 
adverse outcome after catheter ablation for AF. Spe-
cifically, women were on average older (64±8 versus 
57±10 years; P<0.001) and had a lower glomerular fil-
tration rate (74±18 versus 82±19 mL/min per 1.73 m2; 
Table 2. Univariate Analysis of Clinical Outcomes (Primary Efficacy End Point, Cardiovascular 
Rehospitalization, and Repeat Ablation) Against 22 Baseline Patient Characteristics
Baseline Characteristics* 
(N=750)
Primary End Point CV Rehospitalization Repeat Ablation
HR (95% CI)
Univariate  
P Value HR (95% CI)
Univariate  
P Value HR (95% CI)
Univariate  
P Value
Age, y 1.01 (1.00–1.02) 0.168 1.02 (1.00–1.04) 0.012† 1.00 (0.98–1.03) 0.653
Body mass index, kg/m2 0.99 (0.97–1.02) 0.505 1.03 (1.00–1.06) 0.035† 1.00 (0.96–1.04) 0.994
Systolic BP, mm Hg 1.00 (0.99–1.01) 0.689 1.01 (1.00–1.01) 0.034† 1.00 (0.99–1.01) 0.627
Diastolic BP, mm Hg 1.00 (0.99–1.01) 0.814 1.00 (0.98–1.01) 0.451 0.99 (0.98–1.01) 0.379
Diabetes mellitus, type I or II 1.10 (0.73–1.66) 0.640 1.33 (0.85–2.06) 0.209 1.12 (0.59–2.15) 0.730
GFR, mL/min per 1.73 m2 1.00 (0.99–1.01) 0.822 1.00 (0.99–1.01) 0.476 1.00 (0.99–1.01) 0.718
Female sex 1.34 (1.06–1.70) 0.015‡ 1.43 (1.10–1.86) 0.008† 1.19 (0.81–1.73) 0.370
History of AF, y 1.02 (1.00–1.04) 0.052 1.00 (0.98–1.03) 0.900 1.03 (1.00–1.06) 0.039§
History of atrial flutter 0.98 (0.72–1.34) 0.913 1.14 (0.82–1.59) 0.447 1.21 (0.77–1.92) 0.410
History of CAD 0.69 (0.42–1.10) 0.121 1.20 (0.77–1.87) 0.414 0.61 (0.27–1.40) 0.245
Hyperlipidemia 1.13 (0.88–1.46) 0.329 1.31 (1.00–1.73) 0.054 1.11 (0.75–1.67) 0.596
Hypertension 1.07 (0.84–1.35) 0.603 1.63 (1.23–2.16) 0.001† 1.23 (0.84–1.82) 0.287
NYHA I or II‖ 1.25 (0.97–1.60) 0.079 1.21 (0.91–1.60) 0.186 1.04 (0.69–1.56) 0.861
Left atrial volume, mL¶ 1.00 (0.99–1.01) 0.479 1.01 (1.00–1.02) 0.122 1.01 (0.99–1.02) 0.560
LVEDD, mm¶ 1.00 (0.98–1.02) 0.949 1.01 (0.99–1.04) 0.258 1.01 (0.98–1.05) 0.489
LVEF, %¶ 0.99 (0.97–1.01) 0.209 0.99 (0.97–1.01) 0.279 0.99 (0.96–1.02) 0.536
Left atrial diameter, mm¶ 1.02 (1.00–1.04) 0.051 1.02 (1.00–1.04) 0.111 1.00 (0.97–1.04) 0.885
PCI 0.80 (0.45–1.43) 0.455 1.13 (0.65–1.98) 0.665 0.52 (0.16–1.64) 0.263
Peripheral artery disease 1.82 (0.45–7.32) 0.398 0.91 (0.13–6.50) 0.926 2.30 (0.32–16.5) 0.406
Prior DCCV 1.37 (1.05–1.78) 0.021‡ 1.32 (0.98–1.77) 0.067 1.16 (0.75–1.78) 0.508
Prior myocardial infarction 0.40 (0.13–1.24) 0.111 0.52 (0.17–1.64) 0.266 0.39 (0.05–2.80) 0.350
Prior stroke or TIA 0.88 (0.47–1.66) 0.703 1.47 (0.80–2.70) 0.210 1.00 (0.37–2.70) 0.992
AF indicates atrial fibrillation; AVS, aortic valve stenosis; BP, blood pressure; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CI, 
confidence interval; CV, cardiovascular; DCCV, direct current cardioversion; GFR, glomerular filtration rate; HR, hazard ratio; LVEDD, left ventricular end-
diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; and TIA, transient 
ischemic attack.
*AVS and CABG were not included in the analysis because prevalences were too low for meaningful statistical evaluation (0.1% of subjects had AVS and 
0.6% of subjects had prior CABG at baseline).
†Significant univariate terms when cardiovascular rehospitalization is the outcome.
‡Significant univariate terms when primary efficacy is the outcome.
§Significant univariate terms when repeat ablation is the outcome.
‖NYHA III and IV were excluded from the trial.
¶Left atrial dimension data reported for 584 subjects, left ventricular ejection fraction data reported for 510 subjects, left ventricular end-diastolic 
dimension data reported for 411 subjects, and left atrial volume data reported for 87 subjects.
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P<0.001) than men. Although not statistically significant, 
there was also a trend for a clinical history of hyperten-
sion to be more prevalent in women (62% versus 55%; 
P=0.058). By contrast, the female cohort also presented 
with clinically favorable baseline characteristics, namely, 
a lower prevalence of prior atrial flutter (11% versus 
21%; P<0.001) and coronary artery disease (5% versus 
10%; P=0.022), and smaller left atria (left atrial diam-
eter, 39.9±6.5 versus 41.2±5.8 mm; P=0.012). Addition-
al statistically different but clinically similar differences 
emerged between female and male cohorts, including 
left ventricular end-diastolic diameter (48±5 versus 51±7 
mm; P<0.001), left ventricular ejection fraction (64±6% 
versus 62±7%; P=0.004), and diastolic blood pressure 
(77±11 versus 80±11 mm Hg; P<0.001).
Efficacy After PS Adjusting for Baseline 
Differences
All female (n=209) and male (n=327) subjects with 
complete baseline covariates were included in the PS 
analysis (Figure 1). PS stratified into 5 quintiles balanced 
across the baseline covariates revealed no statistical dif-
ferences between groups (all interaction tests, P>0.05; 
Table I in the Data Supplement). Women continued to 
have worse outcomes than men. Specifically, the female 
cohort had a higher risk of primary efficacy failure (HR, 
>1) in 4 of 5 quintiles and a higher risk of cardiovascular 
rehospitalization in all 5 quintiles. The overall PS-adjust-
ed HRs for both the primary efficacy end point (HRPS adj, 
1.51; 95% CI, 1.16–2.18) and cardiovascular rehospi-
talization (HRPS adj, 1.40; 95% CI, 1.15–2.17) were sta-
tistically significant at P<0.05 (Table 4).
Procedural Characteristics by Sex
Table 5 presents the index AF ablation procedural mea-
surements. Mean procedure time during the index 
AF ablation was similar between female and male 
cohorts (131±46 versus 134±50 minutes, respectively; 
P=0.533). Similarly, there were no statistical differences 
between female and male cohorts when examining 
left atrial dwell time (98±37 versus 102±41 minutes, 
respectively; P=0.157) and fluoroscopy time (20±19 
versus 19±14 minutes, respectively; P=0.179). Howev-
er, the length of stay during the index ablation hospital-
ization was significantly longer in women than in men 
(2.4±2.0 versus 1.8±1.2 days; P<0.001).
Safety Events by Sex
The primary safety end point was protocol defined as a 
composite of death from any cause, stroke or transient 
ischemic attack from any cause, and serious adverse 
events.5–7 Serious adverse events included 2 major cate-
gories: (1) cardiac arrhythmias (other than a recurrence 
of AF) that were causally related to the therapeutic 
intervention and (2) procedure-related serious adverse 
events that were judged by the end point review com-
mittee to be causally related to the treatment. In this 
study, more women experienced a primary safety 
adverse event end point throughout the trial than men 
(16% versus 10%; P=0.017; Table 6). Of the 6% dif-
ference in safety event rate between men and women, 
2.8% was attributed to groin site complications.
DISCUSSION
The primary objective of this study was to evaluate the 
association of baseline patient characteristics in the 
FIRE AND ICE data set with 3 clinical outcome measure-
ments of catheter ablation for AF (ie, atrial arrhythmia 
recurrence, cardiovascular rehospitalization, and repeat 
catheter ablation). The study revealed that female sex 
was associated with a 37% increase in the risk of atrial 
arrhythmia recurrence and that subjects with a histo-
Table 3. Multivariable Analysis of Outcomes (Primary Efficacy End Point, Cardiovascular 
Rehospitalization, and Repeat Ablation) Against Baseline Patient Characteristics With Significant 
Univariate Association
Study End Point
Baseline 
Characteristics 
(N=750)
Univariate Multivariable
HR (95% CI) P Value HR (95% CI) P Value
Primary efficacy failure Female sex 1.34 (1.06–1.70) 0.015 1.37 (1.08–1.73) 0.010
Prior DCCV 1.37 (1.05–1.78) 0.021 1.40 (1.07–1.82) 0.013
Cardiovascular 
rehospitalization*
Age, y 1.02 (1.00–1.04) 0.012 1.01 (0.99–1.03) 0.241
BMI, kg/m2 1.03 (1.00–1.06) 0.035 1.02 (0.99–1.05) 0.215
Female sex 1.43 (1.10–1.86) 0.008 1.36 (1.02–1.80) 0.035
Hypertension 1.63 (1.23–2.16) 0.001 1.48 (1.09–2.00) 0.013
Repeat ablation† History of AF, y 1.03 (1.00–1.06) 0.039 NA NA
AF indicates atrial fibrillation; BMI, body mass index; BP, blood pressure; CI, confidence interval; DCCV, direct current cardioversion; HR, hazard 
ratio; and NA, not applicable.
*To avoid collinearity, systolic BP has been excluded from the multivariable model because it is highly correlated with hypertension.
†History of AF was the only variable significant in univariate testing.
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ry of DCCV had a 40% increase in the risk of atrial 
arrhythmia recurrence. In addition to increased pri-
mary efficacy failure, female sex was associated with a 
36% increased risk, and a history of hypertension was 
associated with a 48% increased risk of cardiovascular 
rehospitalization. A longer history of AF was the only 
Figure 2. Kaplan–Meier event-free survival after the index catheter ablation.  
A and B, Primary efficacy end point according to sex and history of direct current cardioversion (DCCV), respectively. Vertical dotted line at 90 d is the predefined 
landmark blanking period used for the primary efficacy end point. Adjusted hazard ratio (HR) from multivariable model (HRMV adj) includes sex and prior DCCV as 
covariates. C and D, Cardiovascular (CV) rehospitalization according to sex and history of hypertension, respectively. HRMV adj includes age, sex, BMI, and hyperten-
sion as covariates. E, Repeat catheter ablation according to prior duration of atrial fibrillation (AF) symptoms (history of AF) before index catheter ablation. History 
of AF is dichotomized at the median value (2.69 y) for the Kaplan–Meier plot, and the data analyses retained the continuous measurements. F, Primary safety end 
point according to sex. CI indicates confidence interval.
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baseline characteristic associated with an increased 
risk of repeat catheter ablation. Specifically, the analy-
sis revealed that each additional year of diagnosed AF 
before the index ablation increased the risk of repeat 
ablation by 3%. Collectively, these data suggest that 
female sex, a history of DCCV or hypertension, and a 
longer history of AF are indicative of a lower success 
rate of catheter ablation for AF and may substantiate 
specialized monitoring or earlier treatment for certain 
patient populations to maximize treatment success.
Predictors of Primary and Secondary AF 
Ablation Outcomes
Analysis of baseline patient characteristics that predict 
secondary end points (eg, cardiovascular rehospitaliza-
tion and repeat catheter ablation) more carefully identi-
fies patients likely to experience clinical success after 
catheter ablation of AF than identifying predictors of 
primary efficacy alone. Studies and subsequent scoring 
systems designed to predict primary efficacy after abla-
tion have been reported,4,10 but here, a large cohort of 
patients was investigated to identify characteristics that 
predict a more complete depiction of clinical success. 
This study demonstrated that a history of DCCV in addi-
tion to female sex increased the risk of AF recurrence 
and that a longer history of AF increased the risk of 
repeat ablation. These results agree with other studies 
that determined history of DCCV, a long history of AF, 
and female sex were associated with AF recurrence after 
catheter ablation.10–12 Additionally, this study deter-
mined that female sex and hypertension independently 
increased the risk of cardiovascular rehospitalization. 
The observation that hypertension increased the risk of 
cardiovascular rehospitalization is consistent with previ-
ous reports that demonstrate an association between 
hypertension and both AF- and cardiovascular-related 
hospitalization.12,13 In our study, we identified female 
sex as the strongest predictor of outcomes after cath-
eter ablation of AF.
Impact of Sex
Our data indicate that female sex was associated with 
≥36% risk of both primary efficacy failure and cardio-
vascular rehospitalization. However, it was challenging 
to assess whether the female cohort had a poorer over-
all health status at the time of enrollment. On average, 
enrolled women were older and had a lower glomeru-
lar filtration rate than men. Although a host of poorly 
understood, sex-dependent physiological and patho-
physiological mechanisms may predispose women to 
develop AF later in life, a review of differences between 
men and women who underwent cardiac ablation pro-
Table 4. Efficacy Outcomes by Sex-Adjusted Baseline Differences (Propensity Score Method)
Propensity Score Quintile Total Women Men
HR (95% CI)
Primary End Point*† CV Hospitalization*‡
Quintile 1 107 10 97 0.84 (0.30–2.35) 1.43 (0.50–4.08)
Quintile 2 107 25 82 1.75 (0.88–3.48) 1.48 (0.68–3.23)
Quintile 3 108 37 71 1.32 (0.71–2.45) 1.02 (0.49–2.13)
Quintile 4 107 57 50 1.94 (1.04–3.62) 1.70 (0.84–3.43)
Quintile 5 107 80 27 1.30 (0.66–2.57) 1.37 (0.68–2.77)
Adjusted overall (inverse-variance weighted)
536 209 327
1.51 (1.16–2.18)§; 
P<0.05
1.40 (1.15–2.17)§; 
P<0.05
CI indicates confidence interval; CV, cardiovascular; HR, hazard ratio; and PS, propensity score.
*Cox proportional hazards regression utilized to calculate HR (95% CI).
†Consistency of HR across quintiles tested by interaction term within a Cox regression model. Primary efficacy is the dependent variable. Sex, PS 
quintile, and sex×PS quintile interaction are covariates. The interaction term is not significant (P=0.64).
‡Consistency of HR across quintiles tested by interaction term within a Cox regression model. CV hospitalization is the dependent variable. Sex, PS 
quintile, and sex×PS quintile interaction are covariates. The interaction term is not significant (P=0.91).
§95% CI calculated by bootstrap methods (10 000 bootstrap samples).
Table 5. Procedural Measurements by Sex
Procedure Characteristics Total (N=750) Women (n=293) Men (n=457) P Value*
Procedure time, min 133±48 131±46 134±50 0.533
Left atrial dwell time, min† 100±40 98±37 102±41 0.157
Fluoroscopy time, min† 19±16 20±19 19±14 0.179
Index ablation length of stay, d 2.1±1.5 2.4±2.0 1.8±1.2 <0.001
Values are mean±SD.
*2-sample t test.
†Left atrial dwell time reported for 711 subjects and fluoroscopy time reported for 744 subjects.
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cedures suggested that women are referred to catheter 
ablation less frequently and at more symptomatic dis-
ease states than men,14 which may play a role in the 
observed age difference between sexes.
Although old age and a lower glomerular filtration 
rate may contribute to adverse outcomes after AF abla-
tion, the differences observed were not large enough to 
account for the entire difference in outcomes between 
women and men observed in our study. For example, 
the 7-year age difference between sexes was univariately 
associated with a 7% increase in primary efficacy failure, 
much less than the observed 37% increase in risk. Further-
more, the difference between sexes does not seem to be 
explained by a composite of the baseline characteristics; 
the increased risk of primary efficacy failure and cardiovas-
cular rehospitalization remained increased in women even 
after PS stratification of patients. Together, these data 
suggest that, regardless of baseline health conditions, sex 
influences clinical outcomes after AF ablation.
Our finding that female sex independently predicted 
both primary efficacy failure and cardiovascular rehospi-
talization is consistent with other reports of an associa-
tion between female sex and an increased risk of recur-
rent AF.1–4,10,15 The ORBIT-AF registry (Outcomes Registry 
for Better Informed Treatment of Atrial Fibrillation) exam-
ined the difference between sexes regarding AF symp-
toms, quality of life, AF treatment, and outcomes and 
found that in addition to baseline characteristic differ-
ences between sexes, women had more often symptom-
atic AF, more functional limitations, and a lower quality 
of life.16 Interestingly, our data indicate that early primary 
efficacy of catheter ablation for AF is similar in both men 
and women up until ≈6 months, at which point abla-
tion efficacy diverges in favor of men (Figure 2). This sex-
dependent late divergence in longer term efficacy is not 
well understood, but it may indicate a less-durable lesion 
in women and a propensity for developing non–pulmo-
nary vein triggers after catheter ablation.
We did not observe statistical differences between 
women and men in either procedure duration or flu-
oroscopy time during the index ablation, but women 
did have a longer length of stay during the index abla-
tion procedure and a higher rate of primary safety end 
points, driven by a higher rate of groin site complica-
tions. Overall, the total number of groin site complica-
tions was low, but the mechanisms that underlie the 
observed sex difference in the incidence of groin site 
complications are unknown.
There is limited data to inform our understanding 
of the sex-related AF disparity and the role sex hor-
mones may play in AF disease progression; however, 
there is evidence of an association between low levels 
of testosterone and risk of AF and progression of atrial 
remodeling during AF in men.17,18 More research needs 
to be conducted on the sex dependence of AF disease 
parameters that affect efficacy and safety when women 
undergo any type of catheter ablation for AF. Further, 
a referral bias against catheter ablation treatment for 
female patients with AF may result in catheter ablation 
of older and disease-progressed women and ultimately 
Table 6. Safety Events by Sex
Primary Safety Event Total (N=750) Women (n=293) Men (n=457) P Value*
Total 91 (12.1) 46 (15.7) 45 (9.8) 0.017
  Groin site complication 23 (3.1) 14 (4.8) 9 (2.0) 0.048
  Atrial arrhythmia 21 (2.8) 9 (3.1) 12 (2.6) 0.821
  Unresolved phrenic nerve injury 10 (1.3) 5 (1.7) 5 (1.1) 0.524
  Cardiac tamponade or pericardial effusion 6 (0.8) 4 (1.4) 2 (0.4) 0.216
  Pulmonary or bronchial complication 6 (0.8) 1 (0.3) 5 (1.1) 0.413
  Stroke or TIA from any cause 4 (0.5) 2 (0.7) 2 (0.4) 0.646
  Transient neurological complication 4 (0.5) 2 (0.7) 2 (0.4) 0.646
  Dyspnea 3 (0.4) 1 (0.3) 2 (0.4) 1.000
  Gastrointestinal complication 3 (0.4) 2 (0.7) 1 (0.2) 0.564
  Other, nonarrhythmia cardiac complications 3 (0.4) 1 (0.3) 2 (0.4) 1.000
  Death 2 (0.3) 1 (0.3) 1 (0.2) 1.000
  Anxiety 1 (0.1) 1 (0.3) 0 (0) 0.391
  Contrast media reaction 1 (0.1) 0 (0) 1 (0.2) 1.000
  Contusion 1 (0.1) 1 (0.3) 0 (0) 0.391
  Esophageal ulcer 1 (0.1) 1 (0.3) 0 (0) 0.391
  Hematuria 1 (0.1) 0 (0) 1 (0.2) 1.000
  Local edema 1 (0.1) 1 (0.3) 0 (0) 0.391
Values are n (%). TIA indicates transient ischemic attack.
*P value for total safety events calculated by log-rank test. P value for safety event components calculated with Fisher exact test.
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impair successful outcomes in this patient population.14 
As future clinical evaluations are conducted, it will be 
important to acknowledge that female sex in addition 
to a history of DCCV or hypertension or a long dura-
tion of AF may decrease the likelihood of a successful 
ablation outcome and skew clinical trial results. Con-
sequently, more aggressive monitoring and effective 
treatment is necessary in these patient cohorts.
Study Limitations
This study utilized the database from the FIRE AND ICE 
trial to assess the association between baseline patient 
characteristics and clinical outcomes. Multivariable 
models were used to investigate associations between 
baseline characteristics and patient outcomes. Statisti-
cally significant associations in the multivariable mod-
els do not necessarily prove any hypothesis, but they 
do provide supporting evidence to other publications. 
Indeed, a sex effect was observed in this trial, but it may 
be limited by the data that were available.
Although sex had the largest impact of the 22 char-
acteristics that were collected at baseline, other (poten-
tially important) uncollected baseline characteristics may 
have had important contributions to our observations. 
A PS analysis method was used in an attempt to under-
stand the difference in efficacy observed between sex-
es, and the results suggested that the large differences 
in efficacy we observed could not be explained by the 
baseline covariates collected (including the mean age 
difference). However, there may be additional baseline 
variables that underlie the observed differences, such as 
the frequency and duration of AF episodes, which were 
not collected at the time of enrollment.
Conclusions
Our study identified select baseline patient characteristics 
that were associated with relevant clinical outcomes after 
catheter ablation of AF. Regardless of the catheter ablation 
modality, female sex and a history of DCCV were indepen-
dently associated with recurrence of AF. Also, female sex 
and hypertension independently predicted an increased 
rate of cardiovascular rehospitalization. Lastly, the patient’s 
history (duration) of AF was associated with a higher risk 
of repeat ablation. Although the risk of an adverse out-
come after catheter ablation in female patients with AF 
mandates further investigation (because it is possible that 
not all critical baseline covariates were collected), these 
results join a growing collection of literature that supports 
earlier AF detection and treatment to enhance efficacy in 
populations that predict poorer clinical outcomes.
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